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induction and the subsequent combination with 
a proliferation signal inhibitor could potentially 
generate protolerogenic immunological eﬀ ects (like 
so-called prope, or near, tolerance and upregulated 
T regulatory cells).13 Prevention of cumulative 
alloimmunological injury to the graft from subclinical 
rejection and acute and chronic (donor-speciﬁ c) 
antibody-mediated rejection could potentially 
translate into measurably better graft function and 
survival after 5 years. Alemtuzumab with sirolimus 
could reduce nephrotoxicity and cardiovascular and 
metabolic adverse eﬀ ects through avoidance of 
calcineurin inhibitors. However, given the complexity 
of cardiovascular morbidity and mortality after renal 
transplantation, improvement in a few laboratory 
results in a clinical trial is a long way from achievement 
of improvements in the disease course over 5 years. 
Ideally, these goals would all be achieved without excess 
malignancies and opportunistic infections.
Irrespective of the current and anticipated long-term 
results of the 3C Study, investigators will question the 
cause of the results. This will be a diﬃ  cult question 
to answer because the 3C investigators changed all 
parts of the standard of care immunosuppressive 
regimen (the type of induction drug, the dose of 
calcineurin inhibitor and mycophenolate, and even 
the use of corticosteroids) rather than one element 
only.3 6 months later, they changed the regimen again. 
Therefore, the 3C Study will not only address its own 
predeﬁ ned hypotheses, but will also represent a test 
case for what type of trials in clinical transplantation 
are needed to regain some of the academic vigour and 
pharmaceutical impetus towards development of new 
pipelines for novel immunosuppressive drugs.
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In 1900, Simon Flexner, while visiting Manila, 
Philippines, isolated a bacterium from two patients 
with “red [bloody] diarrhoea” that he thought was the 
same as Shiga’s Shigella dysenteriae. However, in 1902, 
Martini and Lentz1 showed that this bacterium was a 
distinct microbe, Bacterium ﬂ exneri, renamed by Ewing2 
as Shigella ﬂ exneri.
This organism is likely to have been the most common 
cause of dysentery in the British Expeditionary Force 
in France in World War 1. Modern gunnery made it 
necessary to provide cover for the troops in trenches. 
Insuﬃ  cient drainage of the trenches coupled with poor 
hygiene and no provision for the disposal of excreta 
meant that soldiers had to survive, often knee deep or 
worse, in foul water. Diseases such as bacillary dysentery 
and trench foot were endemic and epidemic in the 
waterlogged trenches, as discussed by Alison Mather 
and colleagues in their accompanying Case Report.3
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Genome sequencing of an early World War 1 isolate 
of S ﬂ exneri, which Kate Baker and colleagues4 describe 
in this issue of The Lancet, gives an in-depth view of 
the microbe’s evolution over the past 100 years. The 
changes mimic those of the ancestral Escherichia coli as it 
developed into Shigella, species that are still regarded as 
a clade of E coli.5 The diﬀ erences reported between E coli, 
the descendant enteroinvasive E coli (EIEC), and Shigella 
are often indistinct (analysis using matrix-assisted 
laser desorption/ionisation with time-of-ﬂ ight mass 
spectrometry is unable to distinguish these microbes)6 
and they share a common core genome. Molecular-clock 
calculations suggest that Shigella diverged from several 
E coli species between 35 000 and 270 000 years ago.7 
Was this a result of early paleolithic man’s habits, the 
way food was prepared or stored, or perhaps diet? Or, if 
about 35 000 BCE is accepted as the date for S ﬂ exneri’s 
appearance, did it occur when man migrated from Africa 
to Europe? The low infective dose of Shigella might 
explain how hunter-gatherers could have taken a small 
amount of contamination with them when moving to 
new environments.
After the evolution of E coli to Shigella, two pre-
dominant genetic events were reported. Old char-
acter istics were deleted—as a form of reductive 
evolution—with the addition of new characteristics 
that increased patho genicity, such as the loss of 
genes relating to motility, the ﬂ agellar genes, and the 
consequent absence of H antigens. Some fermentative 
catabolic pathways disappeared, accompanied by a loss 
of lysine decarboxylase, the end-product of which is 
cadaverine, which impedes intracellular dissemination of 
Shigella by blocking bacterial escape from phagocytes.8 
Changes in the bacterial cell envelope resulting in no 
K (capsular) antigens have also been reported. However, 
many more insertion sequences, including those related 
to genomic pathogenicity islands, appeared. Insertion 
sequences constitute 7% of the Shigella genome, 
compared with 1·5% of E coli K12.9 Speciﬁ c virulence 
factors, such as adhesins and EIEC toxin, which damage 
intestinal mucosal epithelium and precipitate bleeding,10 
were also acquired. Antigenic variation of the O antigen 
helps the bacterium to avoid the immune response, and 
genetic changes in the large virulent plasmid (which is 
responsible for diﬀ erent pathogenic determinants such 
as the T3 secretory system) tend to parallel those found 
in the bacterial chromosome. 
Baker and colleagues4 show the same trend occurring 
over the past 100 years in the S ﬂ exneri isolate from 
World War 1, with insertion sequences facilitating the 
gain of some antimicrobial resistance elements and 
the discovery of unique pseudogenes. New virulence 
factors also appeared, such as shigella enterotoxin 1,11 
and the number of pathogenicity islands increased. The 
occurrence of a new serotype Xv from China, replacing 
the more common Asian serotype of S ﬂ exneri type 2a 
but remaining in the same serotype cluster, renders any 
immunity obtained from the old 2a serotype irrelevant.12 
The large plasmid was lost in the World War 1 isolate, 
presumably because of serial passage. Since this plasmid 
carries many virulence genes, such as those promoting 
type 3 secretion system eﬀ ectors and SK2, which 
assists intercellular and intracellular spread of Shigella,13 
only chromosomal changes could be investigated. 
The mutation of the variant (v) portion in the 
(S ﬂ exneri 2a) Xv Chinese serotype, unlike all the other 
genes for serotypes, is a plasmid mutation.14
Good hygiene, especially when preparing food, and 
reliable sanitation are the best prevention against 
bacillary dysentery. There are no signiﬁ cant non-human 
hosts, which makes vaccination an ideal solution for 
elimination of the disease. However, although many 
studies are in progress,15 vaccines are not yet available. 
Multiple antibiotic resistance of Shigella means treatment 
is not straightforward, even though some regional 
variation in resistance exists.
The focus on the treatment of soldiers has more 
recently been extended to civilian populations of war 
zones. Admirable in itself, this approach also reduces 
the sources of infection to which soldiers are exposed, 
underlining the role of the military in humanitarian work. 
Nowadays epidemics of bacillary dysentery in the armed 
services are not often reported; rather, they tend to occur 
in refugee camps and in impoverished urban slums.
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The International Society on Thrombosis and 
Haemostasis (ISTH) has declared Oct 13 to be World 
Thrombosis Day, to be held annually from 2014 
onwards. The purpose is to work together with and 
assist local and regional organisations to increase 
awareness of and education about thrombosis.
This date has been chosen because it is the birthday 
of Rudolf Virchow (1821–1902), the founder of cellular 
pathology, who worked in Berlin and Würzburg, 
Germany. He was a remarkable man, paving the way for 
modern medicine along with the Viennese pathologist 
Carl von Rokitansky. Virchow worked not only as a 
pathologist but also did animal experiments, treated 
patients, and advocated public health—pursuing his 
socially minded ideas with such vigour that he was 
forced to leave Berlin at one stage (although re-instated 
at the Charité hospital, in Berlin, 6 years later). Virchow 
was the ﬁ rst to show by autopsy studies that pulmonary 
emboli originate from thrombi in the deep veins of 
the leg, and he suggested three groups of causes for 
thrombosis which were, liberally translated, stasis, 
hypercoagulability, and vessel wall pathology. Being 
the ﬁ rst to use the words thrombosis and embolism,1 
Virchow is rightly seen as the father of modern research 
into thrombosis.
The need to raise awareness of thrombosis 
becomes clear when one reads the paper on the 
global burden of thrombosis published in the 
Journal of Thrombosis and Haemostasis,2 and copublished 
by Thrombosis and Haemostasis, Seminars in Thrombosis, 
Thrombosis Research and Arteriosclerosis, Thrombosis 
and Vascular Biology. Arterial thrombosis (ie, ischaemic 
heart disease and ischaemic stroke) causes more than 
10 million deaths per year worldwide. When years of life 
lost to premature death and years lived with disability 
are looked at jointly, ischaemic heart disease is the 
leading cause of death worldwide. Moreover, the death 
toll of arterial thrombosis has increased by 25–35% 
during the past 20 years, which is determined by two 
rapidly diverging trends: a decrease in industrialised 
countries and an increase in developing countries. 
These are staggering numbers, but, as the report points 
out, a third major contributor to the global burden of 
thrombosis is venous thrombosis (deep vein thrombosis 
and pulmonary embolism). Unfortunately, there is 
much less detailed information available about deaths 
and disability caused by venous thrombosis. The Global 
Burden of Diseases, Injuries, and Risk Factors Study by 
WHO did not include venous thromboembolism as a 
speciﬁ c cause of death or disability.3
Because of the scarcity of data and awareness, the 
ISTH report2 focuses on venous thrombosis and, in 
a painstaking eﬀ ort, all published reports have been 
reviewed and used to assess the global burden it causes. 
What emerges is a bleak picture. The incidence of 
venous thrombosis is not much diﬀ erent from that of 
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